SubsidieMeestersGate2Brain. Medicines beyond barriers.
Gate2Brain develops peptide-shuttles to transport therapeutic drugs across the blood-brain barrier, aiming to treat CNS disorders, particularly pediatric brain tumors.
Projectdetails
Introduction
In 2019, 30 million people worldwide were diagnosed with some form of CNS disorder, and most of them lack effective treatment. This is largely explained by the fact that most developed therapeutic molecules do not contain the appropriate properties to cross the BBB.
Impact of CNS Disorders
Consequently, CNS disorders are the first cause of disability and the second cause of mortality worldwide.
Gate2Brain Technology
Gate2Brain is a technological platform based on a set of small peptide-shuttles that have the capacity to cross the BBB and carry therapeutic cargoes to the CNS that cannot reach the brain unaided.
G2B-002
G2B-002, our flagship product, is a new therapeutic approach to fight against untreatable pediatric brain tumors with an intact BBB.
Delivery Technology
G2B's novel delivery technology provides a non-invasive, non-antigenic, stable, soluble, and receptor-specific way to transport drugs across the BBB to reach the CNS.
Potential Applications
Our technology has the potential to be applied in a wide number of therapeutic areas and in transport through various biological barriers.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.470.759 |
| Totale projectbegroting | € 3.529.656 |
Tijdlijn
| Startdatum | 1-4-2023 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- GATE2BRAIN SLpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Brain Interchange ONE SR—the implantable neuromodulation technology for stroke rehabilitationCorTec aims to develop innovative implantable technology for stroke rehabilitation, enabling new therapies and devices while targeting market approval and $250M in sales by 2030. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
NANO-PL is a hydrogel-based, one-time treatment for glioblastoma that shows promising safety and efficacy, including tumor eradication and improved survival rates in preclinical models.
Brain Interchange ONE SR—the implantable neuromodulation technology for stroke rehabilitation
CorTec aims to develop innovative implantable technology for stroke rehabilitation, enabling new therapies and devices while targeting market approval and $250M in sales by 2030.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Creating an orthogonal gate to the brainThis project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer. | ERC Starting... | € 1.499.136 | 2023 | Details |
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders. | ERC Proof of... | € 150.000 | 2022 | Details |
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
4D Brain-Targeting Nanomedicines for Treating NeurodegenerationThis project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma ImmunotherapyGLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity. | ERC Starting... | € 1.498.175 | 2025 | Details |
Creating an orthogonal gate to the brain
This project aims to revolutionize brain drug delivery by creating a novel orthogonal receptor for efficient transport across the blood-brain barrier, targeting treatments for brain metastatic breast cancer.
Versatile Polypeptide-based Intranasal Drug Delivery Platform(s) to Tackle CNS Disorders.
POLYBRAINT aims to develop an innovative intranasal drug delivery platform to effectively transport biological agents across the blood-brain barrier for treating CNS disorders.
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.
4D Brain-Targeting Nanomedicines for Treating Neurodegeneration
This project aims to develop advanced 4D-brain-targeting nanoparticles using nanotechnology to effectively deliver treatments for neurodegenerative diseases across the blood-brain barrier.
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy
GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.